atbtherapeutics, a biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody,” has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located in the US.   In this agreement, atbtherapeutics and iBio CDMO will work together for the industrialization of the GMP manufacturing process of atbtherapeutics’ atbodies – game-changer biologics of targeted antibody-based therapy in development for...